omniture
logo
Search
南京北恒生物科技有限公司 Nanjing North Hang Seng Material Technology Co. LTD
Media Room

Latest News

rss

Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell therapy for Relapsed or Refractory T Cell Malignancies

NANJING and HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd, a cli...

2022-09-26 21:00 1521

China CDE Approved First Universal CAR-T IND !

NANJING, China, March 17, 2022 /PRNewswire/ -- On March 17, 2022, China National Drug Administratio...

2022-03-17 21:32 1531

CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA

NANJING, China, Jan. 28, 2022 /PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co.,Ltd. ( hereinaf...

2022-01-28 22:00 2627

Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.

NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T ce...

2021-06-20 21:00 2656

Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies

NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechn...

2021-03-24 22:01 20684

Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting

HANGZHOU and NANJING, China, Nov. 10, 2020 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-sta...

2020-11-10 22:30 1513